Kallikrein gene therapy: a new strategy for hypertensive diseases.
The tissue kallikrein-kinin system has been postulated to play a role in blood pressure homeostasis and the pathogenesis of clinical hypertension. To demonstrate the potential therapeutic effects of somatic gene delivery in treating hypertension, we used spontaneously hypertensive rats (SHR) as a model. The gene encoding the human tissue kallikrein was used because of its powerful hypotensive action. The human kallikrein DNA constructs were placed under the control of the metallothionein metal response element, the cytomegalovirus promoter/enhancer or the Rous sarcoma virus 3'-LTR. The human tissue kallikrein DNA constructs were incorporated into adenoviral vectors via homologous recombination. The naked plasmid DNA constructs or adenovirus containing the kallikrein gene were first introduced into kidney 293 cells and the expression of human tissue kallikrein was identified by ELISA. The kallikrein gene was delivered into SHR via intramuscular, intravenous, portal vein, intraperitoneal, and intracerebroventricular routes. A single injection of naked human kallikrein DNA constructs caused a prolonged reduction of high blood pressure for up to 8 weeks. Adenoviral-mediated gene delivery results in high efficiency of human tissue kallikrein expression. Immunoreactive human kallikrein was detected in rat serum at the highest level at 1 day post gene delivery. Portal vein delivery of a reporter gene, AdCMV-LacZ, results in intense staining of beta-galactosidase in rat liver, suggesting that recombinant kallikrein is mainly produced in liver and secreted into the circulation. These results show that kallikrein gene delivery causes a sustained reduction of blood pressure in genetically hypertensive rats and provide important information for a potential gene therapy approach to human hypertension and related diseases.
Chao
J
J
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston 29425-2211, USA.
Chao
L
L
D000818:Animals; D001358:Avian Sarcoma Viruses / Q000235:genetics; D001794:Blood Pressure / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D003587:Cytomegalovirus / Q000235:genetics; D004279:DNA, Viral / Q000008:administration & dosage / Q000378:metabolism; D015967:Gene Expression Regulation, Viral / Q000235:genetics; D017930:Genes, Reporter / Q000235:genetics; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D006973:Hypertension / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D007273:Injections, Intramuscular; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D016234:Kallikrein-Kinin System / Q000235:genetics*; D007610:Kallikreins / Q000008:administration & dosage / Q000235:genetics* / Q000494:pharmacology / Q000627:therapeutic use; D007763:Lac Operon; D008668:Metallothionein / Q000235:genetics; D010957:Plasmids; D011401:Promoter Regions, Genetic; D051381:Rats; D011918:Rats, Inbred SHR; D013997:Time Factors; D020840:Tissue Kallikreins; D001616:beta-Galactosidase / Q000378:metabolism
D004279:DNA, Viral; D008668:Metallothionein; D001616:beta-Galactosidase; D007610:Kallikreins; D020840:Tissue Kallikreins